Spyre’s rheumatoid arthritis plan toppled by subpar TL1A data

Posted inBiotechnology

Phase 2 data on Spyre Therapeutics’ anti-TL1A antibody SPY072 in rheumatoid arthritis have fallen short of expectations, prompting the biotech to deprioritize monotherapy development in the indication.